Surmodics Inc (SRDX) Return on Investment ROI from the third quarter of 2025 to third quarter of 2024 and for the year 2025, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Surmodics Inc   (NASDAQ: SRDX)


Surmodics Inc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Surmodics Inc's ROI in the third quarter of 2025?
Surmodics Inc recorded a cumulative net loss of $-18 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -11.59%.

Within the Healthcare sector 260 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2025 from 2516 to 2897.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2025)
III. Quarter		 (Mar 31 2025)
II. Quarter		 (Dec 31 2024)
I. Quarter		 (Sep 30 2024)
IV. Quarter		 (Jun 30 2024)
III. Quarter
Y / Y Investment Change TTM -5.9 % -3.05 % 1.87 % 5.94 % 13.18 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 150 149 151 158 157
Return On Investment (TTM) -11.59 % -12.92 % -9.16 % -7.18 % -0.87 %
SRDX's Overall Ranking # 2897 # 2516 # 1110 # 0 # 960
Seq. Investment Change TTM -1.11 % -2.28 % -2.06 % -0.58 % 1.88 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -18 -20 -14 -12 -1

SRDX Company Profile >> Back to SRDX Roi Comparisons >> See Annual SRDX Return On Investment



Return On Investment SRDX's Ranking
Within: No.
Industry # 83
Sector # 261
Overall # 2897

Return On Investment Statistics
High Average Low
14.89 %
1.83 %
-25.14 %
(Dec 31 2013)   (Mar 31 2023)



  News about Surmodics Inc Return on Investment ROI

Surmodics Gains FDA Approval for Pounce XL Thrombectomy System Amid Financial Challenges

October 1, 2024

In a significant advancement for vascular intervention, Surmodics, Inc. a prominent player in the medical device and in vitro diagnostic technology sector, has announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Pounce XL Thrombectomy System. This new device is designed for the non-surgical removal of thrombi and emboli from peripheral arterial vasculature in vessels ranging from 5 to 10 mm in diameter, thus expanding the company’s Pounce Thrombectomy Platform to include larger peripheral arteries, such as those in the iliac and femoral regions. The Pounce XL Thrombectomy System promises to enhance patient outcomes by providing a minimally invasive option for treating obstructive vascular conditions, which can lead to serious complications if left untreated. This development not only underscores Surmodics commitment to innovation in healthcare but also highlights its strategic focus on addressing the needs of interventional cardiology and vascular surgery.However, despite this promising technological advancement, Surmodics faces a challenging financial landscape. For the twelve months ending in the fourth quarter of 2023, the company recorded a cumulative net loss of $11 million, resulting in a disappointing return on investment (ROI) of -7.22%. Such figures raise concerns for investors and stakeholders, particularly given that 264 other companies within the healthcare sector reported a higher ROI during the same period.





Financial Statements
Surmodics Inc's III. Quarter Investments $ 150 Millions SRDX's Balance sheet
Surmodics Inc's III. Quarter Income $ -5 Millions Quarterly SRDX's Income Statement
SRDX's Income by Division See SRDX's Income by Division


SRDX Annual Return On Investment (Sep 30 2024)
2024		 (Sep 30 2023)
2023		 (Sep 30 2022)
2022		 (Sep 30 2021)
2021		 (Sep 30 2020)
2020
Total Investments in Millions 158 162 126 165 150
Y / Y Investment Growth -2.32 % 28.11 % -23.36 % 9.95 % 7.31 %
Net Income in Millions -12 -2 -27 4 1
Y / Y Net Income Growth - - - 277.29 % -85.21 %
Annual Return On Investment -7.3 % -0.95 % -21.6 % 2.57 % 0.75 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SRDX's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SRDX's Competitors
Subscribers only: Roi for Surmodics Inc's Suppliers
Subscribers only: Return On Investment for SRDX's Customers

Other Ratios
SRDX's Roa SRDX's Inventory Turnover Ratio SRDX's Growth Rates SRDX's Dividend Statistics
SRDX's Profitability Ratios SRDX's Asset Turnover Ratio SRDX's Dividend Growth
SRDX's Roe SRDX's Valuation Ratios SRDX's Financial Strength Ratios SRDX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector ROI

Date modified: 2026-09-26T06:54:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.